Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Next Previous
X
Search
Trial Profile

A phase I investigator initiated inhalation safety trial of AB569 in healthy volunteers.

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitrite (Primary)
  • Indications Burkholderia cepacia infections; Pseudomonal infections; Staphylococcal infections
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 19 Jun 2018 According to an Arch Biopartners media release, the company will seek regulatory guidance from the US FDA in the a pre-Investigational New Drug (pre-IND) meeting for AB-569. This trial will be on hold and will resume again after the IND application is opened and the FDA approves the phase I study.
    • 19 Jun 2018 Arch Biopartners media release, status changed from recruiting to suspended.
    • 27 Mar 2018 According to an Arch Biopartners media release, the first patients were recruited and enrolled in the trial in February 2018. Dr. Ralph Panos is the lead investigator of the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top